Does the media prefer ACAD or ASND?

In the previous week, Ascendis Pharma A/S had 20 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 23 mentions for Ascendis Pharma A/S and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.88 beat Ascendis Pharma A/S's score of 0.66 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 7 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BBIO or ACAD?

In the previous week, BridgeBio Pharma had 3 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 6 mentions for BridgeBio Pharma and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.88 beat BridgeBio Pharma's score of 0.87 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ACAD or SMMT?

In the previous week, Summit Therapeutics had 2 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 5 mentions for Summit Therapeutics and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.88 beat Summit Therapeutics' score of 0.20 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ACAD or EXEL?

In the previous week, Exelixis had 10 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 13 mentions for Exelixis and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.88 beat Exelixis' score of 0.44 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer BMRN or ACAD?

In the previous week, BioMarin Pharmaceutical had 8 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 11 mentions for BioMarin Pharmaceutical and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.88 beat BioMarin Pharmaceutical's score of 0.63 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ACADIA Pharmaceuticals (ACAD) Competitors

$27.29 -0.16 (-0.58%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$27.22 -0.07 (-0.26%)

As of 09/18/2026 07:55 PM Eastern

Compare

ACAD vs. ASND, BBIO, SMMT, EXEL, and BMRN

Should you buy ACADIA Pharmaceuticals stock or one of its competitors? ACADIA Pharmaceuticals's main competitors and comparable companies include Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Summit Therapeutics (SMMT), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

ACADIA Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.14B	4.13	$391M	$2.22	12.29
Ascendis Pharma A/S	$1.05B	14.10	-$258M	$12.89	18.36

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ACADIA Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 20 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 23 mentions for Ascendis Pharma A/S and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.88 beat Ascendis Pharma A/S's score of 0.66 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	7 Very Positive mention(s)	7 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 70.99% compared to ACADIA Pharmaceuticals' net margin of 33.42%. Ascendis Pharma A/S's return on equity of 32.54% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

ACADIA Pharmaceuticals currently has a consensus price target of $34.36, indicating a potential upside of 25.91%. Ascendis Pharma A/S has a consensus price target of $310.75, indicating a potential upside of 31.27%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Ascendis Pharma A/S beats ACADIA Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BridgeBio Pharma presently has a consensus price target of $102.61, indicating a potential upside of 54.05%. ACADIA Pharmaceuticals has a consensus price target of $34.36, indicating a potential upside of 25.91%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	25.94	-$724.93M	-$3.57	N/A
ACADIA Pharmaceuticals	$1.14B	4.13	$391M	$2.22	12.29

In the previous week, BridgeBio Pharma had 3 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 6 mentions for BridgeBio Pharma and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.88 beat BridgeBio Pharma's score of 0.87 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has a net margin of 33.42% compared to BridgeBio Pharma's net margin of -97.03%. ACADIA Pharmaceuticals' return on equity of 9.03% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

Summary

ACADIA Pharmaceuticals beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Summit Therapeutics?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

In the previous week, Summit Therapeutics had 2 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 5 mentions for Summit Therapeutics and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.88 beat Summit Therapeutics' score of 0.20 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ACADIA Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.14B	4.13	$391M	$2.22	12.29
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Summit Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Summit Therapeutics	N/A	-168.94%	-141.92%

ACADIA Pharmaceuticals has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.24, indicating that its stock price is 224% less volatile than the broader market.

ACADIA Pharmaceuticals currently has a consensus price target of $34.36, indicating a potential upside of 25.91%. Summit Therapeutics has a consensus price target of $25.91, indicating a potential upside of 45.14%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats Summit Therapeutics on 12 of the 16 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Exelixis?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

In the previous week, Exelixis had 10 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 13 mentions for Exelixis and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.88 beat Exelixis' score of 0.44 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

ACADIA Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

Exelixis has higher revenue and earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.14B	4.13	$391M	$2.22	12.29
Exelixis	$2.32B	6.23	$782.57M	$3.18	18.35

Exelixis has a net margin of 35.33% compared to ACADIA Pharmaceuticals' net margin of 33.42%. Exelixis' return on equity of 42.17% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Exelixis	35.33%	42.17%	31.76%

ACADIA Pharmaceuticals presently has a consensus price target of $34.36, indicating a potential upside of 25.91%. Exelixis has a consensus price target of $50.29, indicating a potential downside of 13.84%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Exelixis beats ACADIA Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

BioMarin Pharmaceutical has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to BioMarin Pharmaceutical's net margin of 2.14%. ACADIA Pharmaceuticals' return on equity of 9.03% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

ACADIA Pharmaceuticals has lower revenue, but higher earnings than BioMarin Pharmaceutical. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.84	$348.90M	$0.37	172.81
ACADIA Pharmaceuticals	$1.14B	4.13	$391M	$2.22	12.29

BioMarin Pharmaceutical currently has a consensus target price of $89.17, suggesting a potential upside of 39.46%. ACADIA Pharmaceuticals has a consensus target price of $34.36, suggesting a potential upside of 25.91%. Given BioMarin Pharmaceutical's higher possible upside, research analysts plainly believe BioMarin Pharmaceutical is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.70
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, BioMarin Pharmaceutical had 8 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 11 mentions for BioMarin Pharmaceutical and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.88 beat BioMarin Pharmaceutical's score of 0.63 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ACADIA Pharmaceuticals beats BioMarin Pharmaceutical on 10 of the 17 factors compared between the two stocks.

Get ACADIA Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACAD vs. The Competition

Export

Metric	ACADIA Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.70B	$3.88B	$7.24B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	12.29	14.23	275.49	25.40
Price / Sales	4.13	1,434.96	642.70	86.83
Price / Cash	30.76	108.90	76.25	51.42
Price / Book	3.76	15.45	10.46	6.33
Net Income	$391M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-1.94%	-1.21%	0.59%	1.12%
1 Month Performance	-6.03%	-3.29%	-1.74%	-2.39%
1 Year Performance	11.75%	37.74%	18.13%	5.35%

ACADIA Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACAD ACADIA Pharmaceuticals	4.4083 of 5 stars	$27.29 -0.6%	$34.36 +25.9%	+11.8%	$4.70B	$1.14B	12.29	798	Positive News High Trading Volume
ASND Ascendis Pharma A/S	4.7219 of 5 stars	$264.92 +0.5%	$310.00 +17.0%	+19.7%	$16.44B	$814.57M	20.55	1,189	Analyst Downgrade
BBIO BridgeBio Pharma	3.5842 of 5 stars	$72.38 -0.1%	$102.61 +41.8%	+27.2%	$14.16B	$713.07M	N/A	839	Options Volume
SMMT Summit Therapeutics	2.3327 of 5 stars	$18.42 +5.0%	$25.91 +40.7%	-5.5%	$14.00B	N/A	N/A	265
EXEL Exelixis	2.3204 of 5 stars	$56.21 +0.2%	$50.07 -10.9%	+45.5%	$13.91B	$2.44B	17.68	1,077

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACAD) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ACADIA Pharmaceuticals (ACAD) Competitors

ACAD vs. ASND, BBIO, SMMT, EXEL, and BMRN

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does ACADIA Pharmaceuticals compare to Summit Therapeutics?

Summary

How does ACADIA Pharmaceuticals compare to Exelixis?

Summary

How does ACADIA Pharmaceuticals compare to BioMarin Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACAD vs. The Competition

ACADIA Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ACADIA Pharmaceuticals (ACAD) Competitors

ACAD vs. ASND, BBIO, SMMT, EXEL, and BMRN

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

Which has preferable earnings and valuation, ACAD or ASND?

Do institutionals & insiders believe in ACAD or ASND?

Which has more volatility and risk, ACAD or ASND?

Does the media prefer ACAD or ASND?

Is ACAD or ASND more profitable?

Do analysts rate ACAD or ASND?

Summary

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

Do insiders and institutionals believe in BBIO or ACAD?

Do analysts rate BBIO or ACAD?

Which has more volatility & risk, BBIO or ACAD?

Which has better earnings & valuation, BBIO or ACAD?

Does the media prefer BBIO or ACAD?

Is BBIO or ACAD more profitable?

Summary

How does ACADIA Pharmaceuticals compare to Summit Therapeutics?

Does the media refer more to ACAD or SMMT?

Which has better valuation and earnings, ACAD or SMMT?

Is ACAD or SMMT more profitable?

Which has more risk & volatility, ACAD or SMMT?

Do analysts rate ACAD or SMMT?

Do institutionals and insiders have more ownership in ACAD or SMMT?

Summary

How does ACADIA Pharmaceuticals compare to Exelixis?

Does the media refer more to ACAD or EXEL?

Which has more risk and volatility, ACAD or EXEL?

Which has stronger earnings & valuation, ACAD or EXEL?

Is ACAD or EXEL more profitable?

Do analysts prefer ACAD or EXEL?

Do insiders and institutionals have more ownership in ACAD or EXEL?

Summary

How does ACADIA Pharmaceuticals compare to BioMarin Pharmaceutical?

Which has more volatility and risk, BMRN or ACAD?

Is BMRN or ACAD more profitable?

Which has stronger earnings and valuation, BMRN or ACAD?

Do analysts rate BMRN or ACAD?

Do institutionals & insiders believe in BMRN or ACAD?

Does the media prefer BMRN or ACAD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACAD vs. The Competition

ACADIA Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools